Nihon Medi-Physics Co. Ltd. has identified antibody-drug conjugates (ADCs) comprising a peptide-modified antibody targeting B-lymphocyte antigen CD20 covalently linked to a radionuclide-chelating agent through a linker reported to be useful for the diagnosis and treatment of cancer.
Emory University and Medical College of Wisconsin have presented quinazolinone derivatives acting as NADPH oxidase (NOX) inhibitors reported to be useful for the treatment of traumatic brain injury and epilepsy.
Merck Sharp & Dohme Corp. has disclosed plasma kallikrein (KLKB1) inhibitors reported to be useful for the treatment of hereditary angioedema, diabetic macular edema, retinal vein occlusion, wet macular degeneration (exudative) and uveitis.
Heptares Therapeutics Ltd. has presented G protein-coupled receptor GPR35 agonists reported to be useful for the treatment of acute and chronic pain, gastrointestinal and lung diseases.
Integral Biosciences Pvt. Ltd. (IBS) has synthesized oxysterols receptor LXR-β (LXRB) agonists reported to be useful for the treatment of cancer, inflammation and Alzheimer's disease.
Novartis AG has described 3C-like proteinase (3CLpro) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Chemocentryx Inc. has divulged azetidinyl-acetamides acting as atypical chemokine receptor 3 (ACKR3) antagonists reported to be useful for the treatment of cancer and inflammatory disorders.
Leitat Technological Center has patented 1H-pyrazole derivatives acting as sigma nonopioid intracellular receptor 1 (SIGMAR1) and/or sigma intracellular receptor 2 (TMEM97) ligands reported to be useful for the treatment of pain and neurological disorders.
Genhouse Medicine (Suzhou) Co. Ltd. has divulged histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer, idiopathic thrombocytopenic purpura, rheumatoid arthritis, diabetes, multiple sclerosis, lung, alcoholic liver and Alzheimer's diseases, among others.
RSS